Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

    Cancer Categories
    • Lung
    Karmanos Trial ID
    • 2018-065
    NCT ID
    • NCT03645928
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator

    Objective:

    Objective
    To evaluate the efficacy of autologous TIL LN-144/LN-145 when given as a single therapy or in combination with pembrolizumab in patients with metastatic melanoma, HNSCC, or NSCLC by estimating the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) To characterize the safety profile of TIL LN-144/LN-145 when given as single therapy or in combination with pembrolizumab in patients with metastatic melanoma, HNSCC, or NSCLC as measured by any ? Grade 3 treatment emergent adverse event (TEAE) rate
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266